Wendy Stevens
University of the Witwatersrand
306 Papers
1.3K Citations
Wendy Stevens is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 47, co-authored 245 publications. Previous affiliations of Wendy Stevens include St. Vincent's Health System & Radboud University Nijmegen Medical Centre.
Chat about Author
Papers
Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis
Dinesh Khanna,Daniel E. Furst,Philip J. Clements,Yannick Allanore,Murray Baron,L. Czirják,Oliver Distler,Ivan Foeldvari,Masataka Kuwana,Marco Matucci-Cerinic,Maureen D. Mayes,Thomas A. Medsger,Peter A. Merkel,Janet E. Pope,James R. Seibold,Virginia D. Steen,Wendy Stevens,Christopher P. Denton +17 more
- 01 Jan 2017
TL;DR: This state-of-art review provides a historical perspective of the development of the modified Rodnan skin score, summarizes the performance of mRSS as an outcome measure, provides guidance on assessingmRSS, and makes recommendations for incorporation of the mR SS into clinical trials.
Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis
Vanessa Smith,Vanessa Smith,Ariane L. Herrick,Francesca Ingegnoli,Nemanja Damjanov,Rossella De Angelis,Christopher P. Denton,Christopher P. Denton,Oliver Distler,Karinna Espejo,Ivan Foeldvari,Tracy M. Frech,Boris Garro,Marwin Gutierrez,Geneviève Gyger,Geneviève Gyger,Eric Hachulla,Roger Hesselstrand,Annamaria Iagnocco,Cristiane Kayser,Karin Melsens,Karin Melsens,Ulf Müller-Ladner,Sabrina Paolino,Carmen Pizzorni,Mislav Radić,Valeria Riccieri,Marcus H Snow,Wendy Stevens,Alberto Sulli,Jacob M van Laar,Madelon C. Vonk,Amber Vanhaecke,Amber Vanhaecke,Maurizio Cutolo +34 more
TL;DR: Experts in the field of capillaroscopy/microcirculation provide in this very consensus paper their view on image acquisition and analysis, different capillsaroscopic techniques, normal and abnormal capillARoscopic characteristics and their meaning, scoring systems and reliability of image acquisitionand interpretation.
357
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
Andreas Rosenwald,Susanne Bens,Ranjana H. Advani,Sharon Barrans,Christiane Copie-Bergman,Mad-Hélénie Elsensohn,Yaso Natkunam,Maria Calaminici,Birgitta Sander,Birgitta Sander,Maryse Baia,Alexandra Smith,Daniel Painter,Luu Pham,Shuchun Zhao,Marita Ziepert,Ekaterina S. Jordanova,Thierry Jo Molina,Marie José Kersten,Eva Kimby,Wolfram Klapper,J M Raemaekers,Norbert Schmitz,Fabrice Jardin,Wendy Stevens,Eva Hoster,Anton Hagenbeek,John G. Gribben,Reiner Siebert,Randy D. Gascoyne,David Scott,Philippe Gaulard,Gilles Salles,C. Burton,Daphne de Jong,Daphne de Jong,Laurie H. Sehn,Delphine Maucort-Boulch +37 more
TL;DR: The negative prognostic impact of MYC-R in DLBCL is largely observed in patients with MYC double hit/triple-hit disease in which MYC is translocated to an IG partner, and this effect is restricted to the first 2 years after diagnosis.
Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study.
Jacoline E C Bromberg,Samar Issa,Katerina Bakunina,Monique C. Minnema,Tatjana Seute,Marc Durian,Gavin Cull,Gavin Cull,Harry C. Schouten,Wendy Stevens,Josée M. Zijlstra,Joke W. Baars,Marcel Nijland,Kylie D. Mason,Aart Beeker,Martin J. van den Bent,Max Beijert,Michael Gonzales,Daphne de Jong,Jeanette K. Doorduijn +19 more
TL;DR: This intergroup, multicentre, open-label, randomised phase 3 study aimed to investigate the addition of rituximab to a high-dose methotrexate-based chemotherapy regimen in patients with newly diagnosed primary CNS lymphoma.
210
Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease
O. Moore,Nicole S L Goh,Tamera J. Corte,Hannah Rouse,Oliver Hennessy,Vivek Thakkar,J. Byron,Joanne Sahhar,Janet Roddy,Eli Gabbay,Peter Youssef,Peter Nash,Jane Zochling,Susanna Proudman,Susanna Proudman,Wendy Stevens,Mandana Nikpour,Mandana Nikpour +17 more
TL;DR: Extensive disease (>20%) on HRCT at baseline, reported using a semi-quantitative grading system, is associated with a three-fold increased risk of deterioration or death in SSc-ILD, compared with limited disease.
182